Instability of the HLA-E peptidome of HIV presents a major barrier to therapeutic targeting
Zoë Wallace(Immunocore (United Kingdom)), Lucy Dorrell(MRC Human Immunology Unit), Tiaan Heunis(Newcastle University), Luís F. Godinho(Immunocore (United Kingdom)), Andrew Knox(Immunocore (United Kingdom)), Andrew Walker(University of Oxford), Dawn Gibbs‐Howe(Immunocore (United Kingdom)), Sarah Leonard(Immunocore (United Kingdom)), Marcin Dembek(Immunocore (United Kingdom)), Tressan Grant(Immunocore (United Kingdom)), Darren B. Leneghan(Immunocore (United Kingdom)), Richard J. Suckling(Immunocore (United Kingdom)), Jacqui Brener(Immunocore (United Kingdom)), Wilawan Bunjobpol(National Cancer Centre Singapore), José R. Donoso(Immunocore (United Kingdom)), Praveen Singh(Immunocore (United Kingdom)), Rachel L. Paterson(Immunocore (United Kingdom)), Joshua Long(Immunocore (United Kingdom)), Daniel P. Kay(University of Luxembourg)
Cited by 13
Related Papers
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
|Nature Medicine|2021|564
Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization
|Scientific Reports|2016|438
A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans
|Journal of General Virology|2004|210
A surface endogalactanase in Bacteroides thetaiotaomicron confers keystone status for arabinogalactan degradation
|Nature Microbiology|2018|167